New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
07:03 EDTINSYInsys Therapeutics completes human abuse study for Dronabinol Oral Solution
Insys Therapeutics announced the successful completion of a human abuse study for Dronabinol Oral Solution, its proprietary, orally administered liquid formulation of the synthetic cannabinoid dronabinol in development for the treatment of chemotherapy induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS.
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
07:04 EDTINSYInsys Therapeutics receives FDA orphan drug designation to CBD candidate
Insys Therapeutics announced that the FDA has granted orphan drug designation, or ODD, to its pharmaceutical cannabidiol, or CBD, candidate for the treatment of pediatric schizophrenia. This marks the fifth ODD for the company's CBD program.
November 19, 2014
12:04 EDTINSYInsys Therapeutics cannabidiol receives FDA orphan designation
Subscribe for More Information
November 12, 2014
10:00 EDTINSYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:15 EDTINSYInsys Therapeutics downgraded at Oppenheimer
As noted earlier, Oppenheimer downgraded Insys to Perform from Outperform. The firm believes that the stock values Suybsys fairly at current levels, while the company's nearest-term pipeline opportunities will likely not materialize until 2016.
07:55 EDTINSYInsys Therapeutics downgraded to Perform from Outperform at Oppenheimer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use